

02-414-A1 sequence listing.TXT  
SEQUENCE LISTING

<110> Elan Pharmaceuticals, Inc.  
Varghese, John  
Maillard, Michel

<120> Method for Treating Alzheimer's Disease Using Aryl Alkanoic Acid Amides

<130> MBHB-02-414-A1

<150> PCT/US03/18517  
<151> 2003-06-11

<150> US 60/387,880  
<151> 2002-06-11

<160> 9

<170> PatentIn version 3.3

<210> 1  
<211> 13  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> N-terminal biotin

<220>  
<221> MISC\_FEATURE  
<222> (11)..(11)  
<223> Covalent attachment of oregon green

<400> 1

Ser Glu Val Asn Leu Asp Ala Glu Phe Arg Cys Lys Lys  
1 5 10

<210> 2  
<211> 13  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> N-terminal biotin

<220>  
<221> MISC\_FEATURE  
<222> (11)..(11)  
<223> Covalent attachment of oregon green

#7

02-414-A1 sequence listing.TXT

<400> 2

Ser Glu Val Lys Met Asp Ala Glu Phe Arg Cys Lys Lys  
1 5 10

<210> 3  
<211> 22  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> N-terminal biotin

<220>  
<221> MISC\_FEATURE  
<222> (20)..(20)  
<223> Covalent attachment of oregon green

<400> 3

Gly Leu Asn Ile Lys Thr Glu Glu Ile Ser Glu Ile Ser Tyr Glu Val  
1 5 10 15

Glu Phe Arg Cys Lys Lys  
20

<210> 4  
<211> 33  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> N-terminal biotin

<220>  
<221> MISC\_FEATURE  
<222> (32)..(32)  
<223> Covalent attachment of oregon green

<400> 4

Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile  
1 5 10 15

Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe Cys Lys  
20 25 30

02-414-A1 sequence listing.TXT

Lys

<210> 5  
 <211> 33  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Synthetic peptide

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> N-terminal biotin

<220>  
 <221> MISC\_FEATURE  
 <222> (7)..(7)  
 <223> Oxidized cysteine

<220>  
 <221> MISC\_FEATURE  
 <222> (19)..(19)  
 <223> Oxidized cysteine

<220>  
 <221> MISC\_FEATURE  
 <222> (31)..(31)  
 <223> Covalent attachment of oregon green

<400> 5

Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr  
 1 5 10 15

Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala Cys Lys  
 20 25 30

Lys

<210> 6  
 <211> 33  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Synthetic peptide

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> N-terminal biotin

02-414-A1 sequence listing.TXT

<400> 6

Cys Gly Gly Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu  
1 5 10 15

Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu  
20 25 30

Phe

<210> 7

<211> 29

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<400> 7

Cys Gly Gly Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu  
1 5 10 15

Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Asn Leu  
20 25

<210> 8

<211> 9

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<400> 8

Ser Glu Val Asn Leu Asp Ala Glu Phe  
1 5

<210> 9

<211> 30

<212> PRT

<213> Artificial

02-414-A1 sequence listing.TXT

<220>

<223> Synthetic peptide

<400> 9

Ala	Asp	Arg	Gly	Leu	Thr	Thr	Arg	Pro	Gly	Ser	Gly	Leu	Thr	Asn	Ile
1				5					10					15	

Lys	Thr	Glu	Glu	Ile	Ser	Glu	Val	Asn	Leu	Asp	Ala	Glu	Phe
		20						25					30